GB Sciences Initiates Cannabis-based Therapy Clinical Trials Consulting Services Agreement with Worldwide Clinical Trials, Inc.

LAS VEGAS, July 17, 2017 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) has signed a Consulting Services Agreement with Worldwide Clinical Trials, Inc. to evaluate the company's intellectual property portfolio and to assist with pre-IND planning for its proprietary cannabis-based formulations. These pre-IND consulting services will be performed by the Chief Medical and Scientific Officer (CMSO) of Worldwide, Michael F. Murphy, MD, PhD, as the representative of an extended Worldwide team. Dr. Murphy has participated in the IND application process for multiple small molecules and biologics with 19 therapeutic targets, across five divisions of the FDA. Dr. Murphy was also the Clinical Research and Excellence (CARE) Lifetime Achievement Award recipient for 2017. The award is presented annually to an extraordinary individual with exceptional contributions and a consistent history of service to the clinical research industry throughout their career.

According to Dr. Murphy, "Current research and development practices emphasize the importance of coordinated activity by industry, academia, and contract research organizations in the evaluation of innovative products, like those of GB Sciences. The process enhances program efficiency, facilitates the integration of the perspective of diverse stakeholders early in clinical development, and is a testament to GB Sciences' strategic vision for the development of their portfolio of products. Worldwide is very pleased to be a contributor to that process, and the state-of-the-art technology which it reflects."

Growblox Life Sciences LLC, a wholly owned subsidiary of GB Sciences, Inc., has filed three provisional patent applications to protect complex mixtures derived from the cannabis plant, which address twenty-six different disease-specific formulations within the Company's intellectual property portfolio. On April 21, 2017, the Company held a Drug Development Strategy Meeting in Las Vegas, co-chaired by Dr. Murphy, and GB Sciences' Chief Science Officer, Dr. Andrea Small-Howard.  Reviewing the scientific validation and market factors related to the development of these twenty-six disease-specific formulations formed the basis of the criteria for selecting three disease-specific formulations from the portfolio for further development by Growblox Life Sciences.

The Company will now focus its resources on the development of: a) two formulations that will be prepared for pilot human studies in the Nevada market and b) one formulation that will be put through pre-clinical studies prior to an IND-filing for official FDA-registered clinical trials.

"We are honored to be working with Dr. Michael Murphy and the industry experts at Worldwide Clinical Trials to evaluate our portfolio and to create the pre-IND plan for the development of our cardiovascular therapies and to design our pilot studies for evaluating the effectiveness of both our Parkinson's disease and chronic pain formulations," said Dr. Andrea Small-Howard, Chief Science Officer of GB Sciences, Inc.

About Worldwide Clinical Trials

Worldwide Clinical Trials employs more than 1,400 professionals around the world, with offices in North and South America, Eastern and Western Europe, Russia and Asia. Founded by physicians committed to advancing medical science, Worldwide is out to change how the world sees CROs – in the best possible way. From early phase and bioanalytical sciences through late phase and post-approval, we provide world-class, full-service drug development services. With infrastructure and talent spanning 60 countries, we execute predictable, successful studies with operational excellence across a range of therapeutic areas, including neuroscience, cardiovascular diseases, immune-mediated inflammatory disorders (IMID) and rare diseases. We never compromise on science or safety. We're never satisfied with the status quo. We're the Cure for the Common CRO. For more information, visit Worldwide.com.

About Growblox Life Sciences, LLC.

Growblox Life Sciences is a wholly owned subsidiary of GB Sciences, Inc. GB Sciences (GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development.  The Company's goal is creating safe, standardized, medical-grade, cannabinoid therapies that target a variety of medical conditions.  To learn more about GB Sciences, Inc., go to: http://gbsciences.com.

Forward-Looking Statements

This press release may contain statements relating to future results or events, which are forward-looking statements.  Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements.  These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control.  It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements.  Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov.  All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware. 

Note:  Although the Company's research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.

Contact Information

Corporate:
GB Sciences, Inc., 3550 West Teco Ave., Las Vegas, NV 89118
866-721-0297, or 
Liz Bianco Publicity Director, liz@gbsciences.com, http://gbsciences.com
Tom Acuragi, COO, tom@gbsciences.com

View original content:http://www.prnewswire.com/news-releases/gb-sciences-initiates-cannabis-based-therapy-clinical-trials-consulting-services-agreement-with-worldwide-clinical-trials-inc-300482865.html

SOURCE GB Sciences, Inc.